Shanghai Pharmaceuticals
Shanghai Pharmaceuticals (Chinese: 上海医药, also referred as Shanghai Pharma) is a Chinese pharmaceutical company. The organization develops and distributes pharmaceutical products and operates in domestic and international markets. 

Shanghai Pharma is the largest pharmaceutical and the first A+H listed company in China to be dual-listed by Shanghai and Hong Kong Stock Exchanges. As of year 2020, the company made its presence to the Global Fortune 500 list with the ranking of 473, overall and 124 among 21 other Chinese companies on the list.

Shanghai Pharmaceuticals was founded in 1994 and is headquartered in Shanghai. As an investment holding company, it is actively engaged in research, manufacturing and distribution of pharmaceutical and healthcare products in China, that develops and distributes traditional Chinese and chemical drugs, chemical, biochemical and healthcare goods that are applied in various therapeutic fields, including immunoregulation and anti-cancer, immune system and digestion, cardiovascular and anti-infection, nervous system and mental disorder. Shanghai Pharma also offers logistics, warehousing and other value-added pharmaceutical supply chain and related support services to the pharmaceutical manufacturers and distributors such as hospitals and retail pharmacies, in addition to running a network of retail drug stores and around 1,800+ chained pharmacies, operating in 16 provinces.

In November 2017, Shanghai Pharma announced the acquisition of U.S. based pharmaceutical distributor Cardinal Health's China operations for about $557 million. The deal made Shanghai Pharmaceuticals the largest distributor for imported drugs in China and the second largest distributor in the overall pharmaceutical distribution. Cardinal is the third largest pharmaceutical company in the United States, which prior to the deal was the eighth largest pharmaceutical company in China. The acquisition strategy was considered a part of its two-stage approach to growth with the central research and development, as it is reported that the company spends between $100 million to $150 million every year on the research and development, which is about 15% to 20% of its profit.
Q185614
Chinese
Concept
Q507443
pharmaceutical
Concept
Q2087302
largest pharmaceutical
Concept
Q148
China
LOC
Q739514
Shanghai
ORG
Q496672
Hong Kong Stock Exchanges
ORG
Q76615
Global Fortune 500
EVE
Q3242970
Chinese companies
UNK
Q8686
Shanghai
LOC
Q219577
holding company
Concept
Q8386
pharmaceutical
Concept
Q6554101
healthcare products
Concept
Q148
China
LOC
Q1059
immune system
Concept
Q11978
digestion
Concept
Q11068
cardiovascular
Concept
Q9404
nervous system
Concept
Q177777
logistics
Concept
Q181623
warehousing
Concept
Q30
U.S.
LOC
Q902397
Cardinal Health
ORG
Q5254772
pharmaceutical distribution
Concept
Q30
United States
LOC
Q276099
research and development
Concept
Q104876809
Shanghai Pharmaceuticals
UNK
Q104876809
Shanghai Pharmaceuticals
UNK
Q104876809
Shanghai Pharmaceuticals
UNK
2020-01-01T00:00:00Z^^http://www.w3.org/2001/XMLSchema#dateTime
2020
DATE
1994-01-01T00:00:00Z^^http://www.w3.org/2001/XMLSchema#dateTime
1994
DATE
2017-11-01T00:00:00Z^^http://www.w3.org/2001/XMLSchema#dateTime
November 2017
DATE
+21^^http://www.w3.org/2001/XMLSchema#decimal
21
NUMBER
+16^^http://www.w3.org/2001/XMLSchema#decimal
16
NUMBER
+557^^http://www.w3.org/2001/XMLSchema#decimal
557
NUMBER
+100^^http://www.w3.org/2001/XMLSchema#decimal
100
NUMBER
+150^^http://www.w3.org/2001/XMLSchema#decimal
150
NUMBER
+15^^http://www.w3.org/2001/XMLSchema#decimal
15
NUMBER
+20^^http://www.w3.org/2001/XMLSchema#decimal
20
NUMBER
country
stock exchange
stock exchange
country
country
country